Transient receptor potential vanilloid 1 (TRPV1) receptors are expressed in nociceptive neurons of rat dorsal root ganglions (DRGs) and mediate inflammatory pain. Nonspecific inhibition of protein-tyrosine phosphatases (PTPs) increases the tyrosine phosphorylation of TRPV1 and sensitizes TRPV1. However, less is known about tyrosine phosphorylation's implication in inflammatory pain, compared with that of serine/threonine phosphorylation. Src homology 2 domain-containing tyrosine phosphatase 1 (Shp-1) is a key phosphatase dephosphorylating TRPV1. In this study, we reported that Shp-1 colocalized with and bound to TRPV1 in nociceptive DRG neurons. Shp-1 inhibitors, including sodium stibogluconate and PTP inhibitor III, sensitized TRPV1 in cultured DRG neurons. In naive rats, intrathecal injection of Shp-1 inhibitors increased both TRPV1 and tyrosine-phosphorylated TRPV1 in DRGs and induced thermal hyperalgesia, which was abolished by pretreatment with TRPV1 antagonists capsazepine, BCTC, or AMG9810. Complete Freund's adjuvant (CFA)-induced inflammatory pain in rats significantly increased the expression of Shp-1, TRPV1, and tyrosine-phosphorylated TRPV1, as well as the colocalization of Shp-1 and TRPV1 in DRGs. Intrathecal injection of sodium stibogluconate aggravated CFA-induced inflammatory pain, whereas Shp-1 overexpression in DRG neurons alleviated it. These results suggested that Shp-1 dephosphorylated and inhibited TRPV1 in DRG neurons, contributing to maintain thermal nociceptive thresholds in normal rats, and as a compensatory mechanism, Shp-1 increased in DRGs of rats with CFA-induced inflammatory pain, which was involved in protecting against excessive thermal hyperalgesia.
Introduction
The transient receptor potential vanilloid 1 (TRPV1) receptor, a nonselective cation channel activated by capsaicin, heat (.43˚C), and protons (pH , 6) 3,4 transduces noxious heat stimuli in nociceptive dorsal root ganglion (DRG) neurons and mediates complete Freund's adjuvant (CFA)-induced inflammatory pain. 5 The activation of TRPV1 is regulated by its phosphorylation status that depends on balanced actions of protein kinases and protein phosphatases. 7 Based on their substrate specificity, these protein kinases/phosphatases are further divided into protein serine/ threonine kinases/phosphatases, protein-tyrosine kinases (PTKs)/ phosphatases, and dual-specificity kinases/phosphatases. 24 The serine/threonine phosphorylation of TRPV1 has been extensively studied; protein serine/threonine kinases, including protein kinase A (PKA), protein kinase C (PKC), Ca 21 /calmodulin-dependent protein kinase II (CaMK II), protein kinase D1 (PKD1), and cyclin-dependent protein kinase 5 (Cdk5), phosphorylate TRPV1 at specific residues and sensitize TRPV1 7, 27 ; however, protein serine/threonine phosphatases such as protein phosphatase 2B (PP2B) dephosphorylate TRPV1 and mediate TRPV1 desensitization. 20, 22 Tyrosine phosphorylation is important for TRPV1 activation as well. The PTK Src increases TRPV1 tyrosine phosphorylation at Tyr200, leads to trafficking of TRPV1 to the plasma membrane, and thus enhances TRPV1 responses in DRG neurons. 12, 29 Complete Freund''s adjuvant-induced inflammatory pain is relieved by TRPV1 antagonism or Src deficiency. 5, 18, 21, 28 Nonspecific protein-tyrosine phosphatase (PTP) inhibition also increases the tyrosine phosphorylation of TRPV1. 12, 29 Src homology 2 domaincontaining tyrosine phosphatase 1 (Shp-1) is a key PTP that dephosphorylates TRPV1. It abolishes increased TRPV1 tyrosine phosphorylation by Src in cultured HEK-293 cells, 29 whereas Shp-1 mutant mice exhibit systemic inflammation and thermal hyperalgesia. 9 Shp-1 exists in the central nervous system, 23 but its localization in DRGs has not been reported nor has its potential role in inflammatory pain. In this study, we examined the expression pattern of Shp-1 in rat DRG neurons and investigated its modulation over TRPV1 and CFA-induced inflammatory pain.
Materials and methods

Animals
Adult male Sprague-Dawley rats (160-180 g) were provided by the Department of Laboratory Animal Sciences, Peking
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Lentivirus packaging
pMig plasmid harboring human Shp-1 was a kind gift from Dr Toshiaki Kawakami (La Jolla Institute for Allergy and Immunology, La Jolla, CA). The sequence coding Shp-1 was amplified from pMig plasmid with polymerase chain reaction (PCR) and cloned into a lentivirus (LV) packaging vector GV287 (GeneChem, Shanghai, China) with an ubiquitin promoter. The lentiviral vectors were constructed, and the lentiviruses (LVShp-1 and LV-GFP) were packaged by Shanghai Jikai Gene Chemistry Technology Inc. 16 LV-GFP without Shp-1 insertion was used as a control.
Drug preparation and application
As a stock solution, PTP inhibitor III (a-bromo-4-(carboxymethoxy)-acetophenone; Merck Millipore) and BCTC (N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carbox-amide, Biomol) were dissolved at 500 mmol/L and 20 mg/mL in dimethyl sulfoxide (DMSO), respectively. AMG9810 (Tocris, Bristol, United Kingdom) and capsaicin (Sigma-Aldrich) were dissolved at 100 mmol/L and 10 mmol/L in ethanol, respectively, and capsazepine (Sigma-Aldrich, St Louis, MO) was dissolved at 100 mmol/L in methanol. The stock solution was freshly diluted in normal saline (NS) or external bath solution; to prepare the vehicle control, in the stock solution, the above drugs were replaced by DMSO, ethanol, or methanol, respectively.
Sodium stibogluconate (SSG; Merck Millipore) was freshly dissolved and diluted in NS, pipette solution, or external solution. Complete Freund's adjuvant (Sigma-Aldrich) was freshly diluted in incomplete Freund's adjuvant (Sigma-Aldrich) to prepare 25% CFA.
Behavior test for heat-induced paw withdrawal latencies
The rat was adapted to the test environment for 15 minutes before experiments. Focused radiant heat was applied onto the left hind paw of the rat, 15 and the latency before the rat withdrew its paw from the heat was taken as the paw withdrawal latency (PWL). The test was repeated 3 times at a minimal 5-minute interval, and the average of PWL values was calculated for each rat. To avoid tissue damage, a cutoff time of 30 seconds was imposed.
Establishment of CFA-induced inflammatory pain
Rats were anaesthetized with 2.5% isoflurane. For the CFA rat, 100 mL CFA was injected into the plantar of left hind paw, whereas for the control rat, an equal volume of NS was injected instead. 17 
Intrathecal delivery of drugs or lentivirus
Rats were anaesthetized with sodium pentobarbital (50 mg/kg). Intrathecal catheter implantation was performed as previously described. 17 A guide cannula was used to puncture the dura at the cauda equina level, and a PE-10 catheter was then implanted to the lumbar enlargement level (3.5-4 cm rostral than the cannula) at the subarachnoid space through the cannula. The outer part of the PE-10 catheter was plugged and fixed onto the skin between the rat ears. A 5-day recovery was given before further experimental procedures. The drug or LV solution was injected with a Hamilton syringe connecting to the PE-10 catheter.
2.7. Western blot detection of Shp-1 and TRPV1 proteins in rat DRGs L4 and L5 DRGs were sonicated in the lysis buffer (in millimole per liter): Tris 100, NaCl 150, ethylenediaminetetraacetic acid (EDTA) 5, phenylmethanesulfonyl fluoride ([PMSF], SigmaAldrich) 1, and 1% Triton X-100 (Sigma-Aldrich), and the pH was adjusted to 7.4. After centrifugation, the supernatants were collected to determine the protein concentration. The protein samples were separated on 10% SDS-PAGE gels and then transferred to polyvinylidene fluoride membranes. After blocking with 5% nonfat milk, the membranes were incubated overnight at 4˚C with mouse monoclonal anti-Shp-1 antibody (1:1000; BD Transduction Laboratories, Franklin Lake, NJ), mouse monoclonal anti-phosphotyrosine antibody 4G10 (1:1000; Merck Millipore), or rabbit polyclonal anti-TRPV1 antibody (1:500; Santa Cruz Biotechnology, Dallas, TX). The signal was detected with SuperSignal West Pico (Pierce). Blots were scanned with CanoScan LiDE 110 controlled by the software MP Navigator EX 4.00 (Canon, Inc, Tokyo, Japan), and band densities were detected and compared with the software Quantity One 4.6.2 (Bio-Rad, Hercules, CA).
Immunoprecipitation
Immunoprecipitation was performed as previously described with modifications. 30 After dissection, L4 and L5 DRGs were mechanically homogenized in the lysis buffer (inmillimole per liter): Tris 100, NaCl 150, EDTA 5, PMSF 1, Na-pervanadate (Sigma-Aldrich) 1, and 1% Triton X-100, and the pH was adjusted to 7.4. After centrifugation at 12,000 rpm for 10 minutes at 4˚C, supernatants were collected to determine the protein concentration. Proteins (500 to 700 mg) were incubated with 4 mg mouse monoclonal anti-Shp-1 antibody, rabbit polyclonal anti-TRPV1 antibody, or normal mouse/ rabbit IgG control (Sigma-Aldrich) overnight, followed by incubation of 40 mL prewashed protein A/G beads for 4 h at 4˚C. The immunoprecipitants were separated by SDS-PAGE gel and probed by anti-Shp-1 (1:1000), anti-TRPV1 (1:500), or mouse monoclonal anti-phosphotyrosine antibody 4G10 (1:1000).
Immunofluorescence detection of colocalization of
Shp-1 and TRPV1 in DRG neurons DRG sections and immunofluorescence were obtained and performed as previously described. 11, 28 Over-anesthetized rats were perfused with NS, followed by 4% paraformaldehyde in 100 mmol/L phosphate buffer. L4 and L5 DRGs were removed, post-fixed in 4% paraformaldehyde for 6 hours, and then dehydrated in graded ethanol series (70% to 100%). After cleaning in xylene for 40 minutes, the tissues were embedded in paraffin wax, finally cut in 8-mm thick serial longitudinal sections, and mounted on gelatin (Sigma-Aldrich type II)-coated glass slides. After deparaffinization and graded hydration, the paraffin sections were blocked in 5% bovine serum albumin and then incubated with anti-Shp-1 (1:250) and anti-TRPV1 (1:500) antibodies overnight at 4˚C, followed by incubation with Alexa Fluor 568-conjugated goat anti-mouse IgG and Alexa Fluor 488-conjugated goat anti-rabbit IgG (both from Invitrogen Life Technologies) for 1 h at room temperature. A fluorescent microscope (Leica DMI4000 B) controlled by Leica Application Suite V4.2 was used for image capture, and the images were then analyzed with Image-Pro Plus software (Media Cybernetics Co, Rockville, MD).
Culture of acutely dissociated DRG neurons
L4 and L5 left DRGs of adult rats were dissected and cultured as previously described. 31 Dorsal root ganglions were digested with type I A collagenase (Sigma-Aldrich) at 3 mg/mL for 45 minutes, followed by 0.25% wt/vol trypsin for 10 minutes at 37˚C. The trypsin digestion was terminated with Dulbecco's minimum essential medium containing 10% fetal bovine serum. The DRGs were mechanically dissociated by a fire-polished Pasteur pipette in fresh Dulbecco's minimum essential medium containing 10% fetal bovine serum. The cell suspension was seeded in poly-D-lysine (Sigma-Aldrich)-coated glass coverslips. Cells were cultivated in Figure 1 . Increased Shp-1 protein levels in ipsilateral L4 and L5 DRGs in rats with CFA-induced inflammatory pain. (A) Thermal hyperalgesia induced by intraplantar injection of CFA in rats. A significant decrease in paw withdrawal latencies was observed from 6 hours to 7 days after CFA injection. (B and C) b-actin served as a loading control. Shp-1 protein expression levels in normal saline (NS) group or CFA group were standardized with that in the naive group (Ctrl). Shp-1 proteins increased at 7 days in the inflammatory pain rats compared with those in the NS rats. Data were represented as mean 6 SEM, n 5 8 in the behavior test and n 5 3 in the Western blot experiment; ***P , 0.001 vs NS group (2-way ANOVA followed by Bonferroni posttests). BL, basal latency. www.painjournalonline.com 599 5% CO 2 incubator at 37˚C for 3 hours before the whole-cell patchclamp recording or the calcium imaging experiments as below.
Calcium imaging analysis of capsaicin-evoked responses in DRG neurons
The cultured DRG neurons were used for calcium imaging. The bath solution contained (in millimole per liter) NaCl 135, CaCl 2 2, KCl 5.4, MgCl 2 1, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 5, and glucose 5.5. The pH was adjusted to 7.4 with NaOH solution. According to the modified method, 2 the acutely dissociated DRG neurons were loaded with 5 mmol/L Fura-2 AM and 0.02% Pluronic F-127 (both were from Invitrogen Life Technologies) in external bath solution for 20 minutes. Then, neurons were washed twice, followed by incubation and recovery in external bath solution for 60 minutes. After 1-minute recording as baseline, the responses of neurons to capsaicin (5 mmol/L) were detected. The bound/unbound calcium ratio (F340/F380) was monitored with a fluorescent microscope (Olympus IX81, Tokyo, Japan) equipped with a Andor iXon 897 EMCDD camera with a monochromator alternating between 340 and 380 nm of wavelength (Lambda DG-4; Sutter Instruments Co, Novato, CA). The microscope was controlled by MetaFluor software (Universal Imaging, Downington, PA).
Whole-cell patch-clamp recording of TRPV1 currents in DRG neurons
The cultured DRG neurons were used for patch-clamp recordings. As described, 12 the external bath solution was identical to that in the calcium imaging experiment, and the pipette solution b-actin served as a loading control. TRPV1 protein expression levels in normal saline (NS) group or CFA group were standardized with that in the naive group (Ctrl). TRPV1 protein levels increased at 7 and 14 days in the inflammatory pain rats compared with those in the NS rats. Data were represented as mean 6 SEM, n 5 3 to 5; ***P , 0.001, *P , 0.05 (2-way ANOVA followed by Bonferroni posttests). (C) The tyrosine phosphorylation of TRPV1 increased at 7 and 14 days in rats with CFA-induced inflammatory pain compared with that in the NS rats. Results were representatives of 4 individual trials.
contained (in millimole per liter) CsCl 30, Cs-aspartate 100, ethylene glycol tetraacetic acid 5, MgCl 2 1, HEPES 5, Na 2 -ATP 5, and Na 2 -GTP 0.4, and the pH was adjusted to 7.2 with CsOH. The filled patch pipette had a resistance of 4 to 7 MV, and the series resistance was compensated to above 75%. The neurons were patched at 270 mV when recording the capsaicin-induced TRPV1 currents. Capsaicin (0.3 mmol/L) was applied for 2 seconds to elicit the inward TRPV1 currents, followed by washout with the external bath solution. Only 1 neuron on each coverslip was recorded to avoid cross-drug contamination. EPC-10 amplifier and Patch master software (HEKA Electronics Inc, Bellmore, NY) were used, and all experiments were conducted at room temperature.
Statistical analysis
Data were presented as mean 6 SEM and analyzed using unpaired t test, paired t test, 1-way analysis of variance (ANOVA) followed by Tukey posttests, or 2-way ANOVA followed by Bonferroni posttests. GraphPad Prism 5 was used for data analysis. Statistically significant difference was considered at P , 0.05.
Results
Increased Shp-1 expression in DRGs of rats with inflammatory pain
To explore the presence of Shp-1 in the DRG of naive rats and its changes in pain, we first established the rat model of inflammatory pain with intraplantar injection of CFA. After CFA injection, rats exhibited thermal hyperalgesia within 6 hours, which lasted 7 days (Fig. 1A) . The PWLs decreased significantly in CFA rats compared with those in control rats at 6 hours, 1, 3, and 7 days (time points: F 6,98 5 13.67, P , 0.001; groups: F 1,98 5 178.3, P , 0.001; time points 3 groups: F 6,98 5 13.20, P , 0.001; P , 0.001 at 6 hours, 1, 3, and 7 days; 2-way ANOVA followed by Bonferroni posttests), and recovered gradually from 14 to 21 days.
Shp-1 protein expression levels were detected with Western blotting in ipsilateral L4 and L5 DRGs at 6 hours, 1, 3, 7, 14, and 21 , and their double staining positive neurons increased significantly at 6 hours and 7 days in rats with CFA-induced inflammatory pain compared with those in NS rats, while TRPV1-positive neurons also increased at 14 days. Data were represented as mean 6 SEM, n 5 3; ***P , 0.001, **P , 0.01, *P , 0.05 (2-way ANOVA followed by Bonferroni posttests). www.painjournalonline.com 601 days after NS or CFA injection (Fig. 1B, C) . Shp-1 protein expression increased significantly at 7 days (P , 0.001) in the CFAinjected rats compared with that in the NS control rats (time points:
F 5,36 5 6.523, P , 0.001; groups: F 2,36 5 8.405, P , 0.01; time points 3 groups: F 10,36 5 7.936, P , 0.001; 2-way ANOVA followed by Bonferroni posttests).
Increased protein expression and tyrosine phosphorylation of TRPV1 in DRGs of rats with inflammatory pain
To investigate the possible role of Shp-1 in TRPV1 modulation in inflammatory pain, the protein expression and tyrosine phosphorylation of TRPV1 were examined in ipsilateral L4 and L5 DRGs at 6 hours, 7, and 14 days after NS or CFA injection. Figure 2A and Figure 2B shows that total TRPV1 protein expression increased significantly at 7 days (P , 0.001) and 14 days (P , 0.05) in CFA rats compared with that in NS rats (groups: F 2,27 5 9.306, P , 0.001; time points: F 2,27 5 0.2983, P 5 0.7445; groups by time points: F 4,27 5 4.889, P , 0.01; 2-way ANOVA followed by Bonferroni posttests). Analysis on the immunoprecipitated TRPV1 with anti-phosphotyrosine antibody 4G10 also revealed increased tyrosine phosphorylation of TRPV1 in the CFA group at 7 and 14 days (Fig. 2C) . (46.0% 6 5.4% vs 31.7% 6 2.1%, P , 0.05, 2-way ANOVA followed by Bonferroni posttests), although its colocalization with Shp-1 did not. Coimmunoprecipitation was used to study possible interactions between Shp-1 and TRPV1 at the protein level (Fig. 4) . Shp-1 proteins were immunoprecipitated by the anti-Shp-1 antibody, together with TRPV1 proteins. Both Shp-1 and TRPV1 were detected in the DRG lysates as a positive control ("input" sample), but not in the normal mouse IgG-negative control ("IgG" sample), demonstrating the specificity of the antibody. It indicated that Shp-1 and TRPV1 bound to each other in DRG neurons.
Shp-1 inhibition sensitized TRPV1 functions in cultured DRG neurons
We next examined the functional significance of interactions between Shp-1 and TRPV1 with calcium imaging. Capsaicin, a specific TRPV1 agonist, activates TRPV1 and induces calcium influx and inward currents in DRG neurons. Extracellular treatment with SSG, a specific Shp-1 inhibitor, at 10 mg/ mL for 60 minutes significantly increased the capsaicininduced calcium influx in DRG neurons compared with the vehicle control (P , 0.05 at 60 minutes, 1-way ANOVA followed by Tukey posttests, Fig. 5A, B) . The incubation time with SSG affected the capsaicin responses significantly (F 2,65 5 3.891, P , 0.05). Another specific Shp-1 inhibitor, PTP inhibitor III, showed similar effects. It also increased capsaicin-induced calcium influx significantly after extracellular application at 200 mmol/mL for 60 minutes (Fig. 5C, D , P , 0.01, unpaired t test). With whole-cell patch-clamp recording, SSG added into the pipette solution at 1 mg/mL immediately (within 10 seconds) amplified the capsaicin-induced current density in SSG-treated neurons compared with that in the vehicle-treated neurons (P , 0.01, unpaired t test, Fig. 5E, F) . These results suggested that intracellular inhibition of Shp-1 sensitized TRPV1 functions.
Shp-1 inhibition induced thermal hyperalgesia in naive rats through TRPV1 sensitization
We next studied the impact of Shp-1 and TRPV1 interactions on pain behaviors in naive rats (Fig. 6) . The Shp-1 inhibitor SSG (10 mg/mL, 20 mL) or NS (20 mL) was intrathecally injected to naive rats at the lumbar enlargement level before PWL measurement. From 30 to 90 minutes after the SSG injection, thermal hyperalgesia developed, ie, PWLs reduced significantly compared with those after the NS injection (groups: F 1,70 5 28.02, P , 0.001; time points: F 4,70 5 2.467, P 5 0.0526; groups 3 time points: F 4,70 5 1.855, P 5 0.1280; P , 0.001 at 30 minutes, P , 0.05 at 60 and 90 minutes; 2-way ANOVA followed by Bonferroni posttests, Fig. 6A ). Another specific Shp-1 inhibitor, PTP inhibitor III, showed similar effects (Fig. 6B) .
Intrathecal injection of PTP inhibitor III (1 mmol/L, 20 mL) reduced PWLs significantly from 30 minutes (groups: F 1,60 5 59.47, P , 0.001; time points: F 4,60 5 11.03, P , 0.001; groups 3 time points: F 4,60 5 7.007, P , 0.001; P , 0.01 at 30 minutes and P , 0.001 from 60 to 120 minutes; 2-way ANOVA followed by Bonferroni posttests). These results indicated that Shp-1 inhibition could induce thermal hyperalgesia in naive rats.
To test whether the effect of Shp-1 inhibition was dependent on the activation of TRPV1, the TRPV1 specific antagonist capsazepine (16 mg, 10 mL) was intrathecally injected 60 minutes before the SSG injection. Sodium stibogluconate did not change basal PWLs in naive rats but almost completely prevented the thermal hyperalgesia induced by the Shp-1 inhibition (groups: F 1,72 5 5.466, P , 0.05; time points: F 5,72 5 4.598, P , 0.01; groups 3 time points: F 5,72 5 4.513, P , 0.01; P , 0.001 at 30 minutes; 2-way ANOVA followed by Bonferroni posttests, Fig. 6C ). Similar effects were observed in experiments with other 2 TRPV1 speicfic antagonists BCTC (300 nmol, 10 mL) and AMG9810 (45 mg, 10 mL). Sodium stibogluconate -induced thermal hyperalgesia was prevented by both BCTC (groups: F 1,72 5 14.31, P , 0.001; time points: F 5,72 5 2.909, P , 0.05; groups 3 time points: F 5,72 5 1.942, P 5 0.0978; P , 0.01 at 30 minutes; 2-way ANOVA followed by Bonferroni posttests, Fig. 6D ) and AMG9810 (groups: F 1,72 5 56.06, P , 0.001; time points: F 5,72 5 9.494, P , 0.001; groups 3 time points: F 5,72 5 4.958, P , 0.001; P , 0.001 at 30 and 90 minutes, P , 0.05 at 60 minutes and P , 0.01 at 120 minutes; 2-way ANOVA followed by Bonferroni posttests, Fig. 6E ).
Thirty minutes after the injection of the Shp-1 inhibitor SSG or NS to naive rats, the tyrosine phosphorylation and protein expression of TRPV1 were examined in acutely dissected L4 and L5 DRGs. Compared with those in the NS group, TRPV1 proteins increased significantly in the SSG group (P , 0.05, unpaired t test, Fig. 6F, G) . The tyrosine phosphorylation of TRPV1 also increased after Shp-1 inhibition through analysis of the immunoprecipitated TRPV1 with anti-phosphotyrosine antibody 4G10 (Fig. 6H) .
These results suggested that Shp-1 inhibited the tyrosine phosphorylation and protein expression of TRPV1 in DRGs to maintain the thermal nociceptive threshold in naive rats. minutes after SSG injection, rats showed more severe thermal hyperalgesia compared with that before SSG injection. (C) At 14 days, the paw withdrawal latencies decreased significantly 30 minutes after SSG treatment compared with those after the NS treatment (D PWL 5 PWL after 2 PWL before ). Data were represented as mean 6 SEM, n 5 8 to 10; ***P , 0.001 (paired t test), **P , 0.01 (2-way ANOVA followed by Bonferroni posttests). BL, basal latency.
Antinociceptive effects of Shp-1 on inflammatory pain
Finally, we observed the effects of Shp-1 inhibition or overexpression on CFA-induced thermal hyperalgesia. The Shp-1 inhibitor SSG (10 mg/mL, 20 mL) or NS (20 mL) was intrathecally injected at the time points of 6 hours, 1, 3, 7, 14, and 21 days after CFA injection in rats. Thermal hyperalgesia was tested before and 30 minutes after SSG or NS injection at each time point. The PWLs did not change after NS injection (Fig. 7A) but significantly decreased after SSG injection at 14 days compared with those before the injection (P , 0.001, paired t test, Fig. 7B ). We further calculated the change of PWL values after NS or SSG injection (DPWL 5 PWL after 2 PWL before ) at each time point and found that the PWLs decreased significantly after the SSG injection compared with those after the NS injection at 14 days (groups: F 1,96 5 4.767, P , 0.05; time points: F 5,96 5 3.895, P , 0.01; groups 3 time points: F 5,96 5 2.427, P , 0.05; P , 0.01 at 14 days; 2-way ANOVA followed by Bonferroni posttests, Fig. 7C ). Taken together, Shp-1 inhibition aggravated thermal hyperalgesia in CFA-induced inflammatory pain.
To overexpress Shp-1 in L4 and L5 DRGs of rats, LV-Shp-1 (1 3 10 7 TU) was injected intrathecally, with LV-GFP (green fluorescent protein, 1 3 10 7 TU) as a control. Seven days after the injection, the green fluorescence of GFP expressed by LV-Shp-1 or LV-GFP was directly observed in left L4 and L5 DRG neurons, indicating a low, stable, and efficient infection of the LV vector (Fig. 8A) . Shp-1 proteins increased significantly in the LV-Shp-1 group compared with those in the LV-GFP group (P , 0.05, unpaired t test, Fig. 8B ). Twenty-five percent CFA was injected to the left hind paws of rats to establish a mild inflammatory pain model. Paw withdrawal latencies showed a significant decrease from 30 to 120 minutes after CFA injection compared with those after the NS injection (P , 0.001, Fig. 8C ). In addition, the thermal hyperalgesia in LV-Shp-1 rats was significantly alleviated compared with that in the LV-GFP control rats (P , 0.05 at 60 minutes, Fig. 8D ). There was significant difference among groups (F 3,92 5 41.09, P , 0.001), time points (F 3,92 5 12.53, P , 0.001) and group 3 time interactions (F 9,92 5 3.158, P , 0.01). These results further suggested that Shp-1 could prevent the development of CFA-induced inflammatory pain.
Discussion
Shp-1 inhibited the activation of TRPV1 and maintained thermal nociceptive thresholds in normal rats
We observed the existence of Shp-1 proteins in rat DRG neurons (Figs. 1 and 3) . Shp-1 colocalized with and bound to TRPV1 in L4 5) and induced thermal hyperalgesia in naive rats (Fig. 6A, B) , which was abolished with pretreatment of TRPV1 antagonists ( Fig. 6C-E) . These results suggested that Shp-1 was involved in the maintenance of thermal nociceptive thresholds through inhibiting the activation of TRPV1 in DRG neurons in normal rats. In a previous study, Shp-1 mutant mice exhibited systemic inflammation and thermal hyperalgesia, 9 but there were no further studies on the underlying mechanisms of the thermal hyperalgesia that may be attributed to changed ion channel functions during systemic inflammation, such as TRPV1, P2X3, acid-sensing ionic channels, ATP-sensitive potassium channel (K ATP ), voltage-gated sodium channels, Kv7, etc. 14, 19 In this study, intrathecal injection of Shp-1 inhibitors induced thermal hyperalgesia in naive rats, which was completely abolished by pretreatment of TRPV1 antagonists ( Fig. 6A-E) , implying the dependence of Shp-1 in nociception on TRPV1 activation.
Shp-1 dephosphorylated TRPV1 and suppressed TRPV1 protein expression in DRG neurons
Thirty minutes after the application of SSG, tyrosine phosphorylation of TRPV1 increased in L4 and L5 DRGs (Fig. 6H) . The PTK Src phosphorylated TRPV1 at Tyr200 and sensitized TRPV1 12, 29 ; nonspecific PTPs inhibition also increased the tyrosine phosphorylation and activation of TRPV1.
12,29 Tyr200 was near the cytosolic N-terminus of TRPV1, and Shp-1 was a non-receptor PTP expressed in the cytoplasma, 1 making it rational that in this study, intracellular application of SSG augmented capsaicin responses more rapidly and required a lower concentration (Fig. 5E, F ) than extracellular application (Fig. 5A, B) . In cultured DRG neurons, TRPV1 was sensitized 60 minutes after extracellular application of the Shp-1 inhibitor SSG but immediately after intracellular application (Fig. 5) .
The expression level of TRPV1 proteins was also upregulated in L4 and L5 DRGs 30 minutes after intrathecal injection of the Shp-1 inhibitor SSG (Fig. 6F, G) . The rapid increase of protein levels most possibly resulted from decreased protein degradation but not increased protein synthesis. The phosphorylation may protect against degradation of TRPV1 proteins. Tyrosine phosphorylation was important for TRPV1 trafficking to plasma membranes 10, 12, 29 and increased the plasma membrane TRPV1 expression within 10 minutes. 10, 25, 29 When Tyr200 of TRPV1 was mutated, Src kinases failed to phosphorylate TRPV1, resulting in TRPV1 translocation from the plasma membrane to the cytoplasma, with the proteasome-dependent degradation of TRPV1 increased and total TRPV1 protein expression decreased. 25 In general, tyrosine phosphorylation of TRPV1 promotes its trafficking to the plasma membrane and prevents TRPV1 degradation. In our experiment, the increase of tyrosine phosphorylation of TRPV1 induced by Shp-1 inhibition may enhance TRPV1 trafficking to the membrane surface, suppress the proteasome-dependent degradation of TRPV1, and finally increase protein expression levels of TRPV1 in DRGs. In other words, Shp-1 and PTKs such as Src may exert balanced regulation over the membrane trafficking of TRPV1, which is important for the physiological metabolism and normal protein expression of TRPV1 in DRG neurons of naive rats. This interesting phenomenon deserves further investigation. In naive rats, the balanced action of Shp-1 and the protein-tyrosine kinase Src determined TRPV1 at a normal level of tyrosine phosphorylation as well as normal nociceptive thresholds. In the upper panel, when Shp-1 was inhibited, the phosphorylation and protein expression of TRPV1 increased, and the thermal hyperalgesia was induced. In the lower panel, when CFA was injected into the hind paws of rats to induce inflammation, the overwhelming Src activation induced more tyrosine phosphorylation of TRPV1, and thus inflammatory pain happened. At the same time, Shp-1 was also upregulated to limit the inflammatory pain, but it was not dominant compared with the Src activation. When Shp-1 was further inhibited, inflammatory pain was aggravated. (B) When Shp-1 was overexpressed before the CFA injection, the tyrosine phosphoration of TRPV1 was inhibited, and thus the CFA-induced inflammatory pain was alleviated.
Shp-1 alleviated CFA-induced inflammatory pain
CFA induced inflammatory pain within 7 days, which recovered from 14 days (Fig. 1) . The tyrosine phosphorylation and protein expression of TRPV1 increased in DRGs after CFA injection (Fig. 2) . Antagonism of TRPV1 inhibited CFA-induced inflammatory pain. 28 Shp-1 inhibition sensitized TRPV1 in cultured L4 and L5 DRG neurons and aggravated CFAinduced inflammatory pain at 14 days (Figs. 5 and 7) . However, overexpression of Shp-1 in L4 and L5 DRG neurons decreased inflammatory pain induced by 25% CFA (Fig. 8) . These results suggested that the dephosphorylation of TRPV1 by Shp-1 protected against inflammatory pain.
Shp-1 proteins and their colocalization with TRPV1 increased in L4 and L5 DRG neurons after CFA injection (Figs. 1 and 3) , which seemed contradictory to the increase of tyrosine phosphorylation of TRPV1 at the same time (Fig. 2) and to Shp-1's protective role in chronic pain through dephosphorylating TRPV1 (Figs. 5-8 ). As we all know, tyrosine phosphorylation of proteins was dynamically and reversibly modulated by PTKs and PTPs. The PTK Src contributed to inflammatory pain through phosphorylating and sensitizing TRPV1. 12, 21, 29 And, a number of studies investigated the interaction between Src and Shp-1. In some cells, Shp-1 activated Src, but in others like HEK-293 cells, Shp-1 did not have such effects. 8, 24, 26 However, Src activated Shp-1 and increased the opportunity of its phosphorylated substrates to be dephosphorylated by Shp-1. 6, 8 When inflammation was induced, the function of Src and Shp-1 might be enhanced simultaneously. They might form an auto-balancing system in CFA inflammatory pain rats to prevent excessive hyperalgesia. Within 14 days after CFA injection, the phosphorylation of TRPV1 by Src might overcome the dephosphorylation by Shp-1; therefore, the tyrosine phosphorylation of TRPV1 increased in DRGs and hyperalgesia happened in rats; after that, the function of Src decreased and Shp-1 helped recover from hyperalgesia. When the balance between Shp-1 and Src was broken, nociceptive thresholds of rats would change. As shown in our results, inhibition of Shp-1 with SGG treatment enhanced tyrosine phosphorylation of TRPV1 (Fig. 6H) and induced thermal hyperalgesia (Fig. 7) , whereas overexpression of Shp-1 alleviated thermal hyperalgesia (Fig. 8) . Therefore, the increase of Shp-1 in DRGs actually protected against Src's effects as a compensatory mechanism. This compensatory mechanism was also reported when Shp-1 served as an autoinhibitory molecule and protected against TNF-a-induced endothelial inflammation; TNF-a increased Shp-1 activity and protein expression, while Shp-1 inhibited TNF-a-induced inflammation. 13 It may imply a universal auto-balancing system when phosphatases like Shp-1 respond to microenvironmental changes, including that in nociception.
We summarize the hypothesis from this study in a schematic diagram as Fig. 9 . Of course, more experiments should be performed to explore the balance between Shp-1 and Src in inflammatory pain, although we focused on the protective role of Shp-1 here.
Conclusions
In conclusion, Shp-1 dephosphorylated TRPV1 and inhibited TRPV1 activation in DRG neurons, contributing to the maintenance of normal thermal nociceptive thresholds. The increase of Shp-1 in DRGs may be involved in the protection against thermal hyperalgesia in CFA-induced inflammatory pain rats as a compensatory mechanism.
